Society of Gynecologic Oncology Virtual Annual Meeting on Women’s Cancer (SGO 2021)

Niraparib PFS benefit in ovarian cancer consistent regardless of time to progression, response to prior chemo

Roshini Claire Anthony, 20210512180001

Niraparib maintenance therapy improved progression-free survival (PFS) in patients with platinum-sensitive recurrent ovarian cancer (PSROC) regardless of time to progression since penultimate platinum chemotherapy or response to last chemotherapy, according to subgroup analyses of the NORA trial.

Hormonal IUD shows potential in early endometrial cancer

Pearl Toh, 20210507140100

Hormonal therapy with a levonorgestrel-releasing intrauterine device (LNG-IUD) led to a high pathological complete response (pCR) rate in women with early-stage endometrial cancer, according to the feMMe trial presented at SGO 2021 Meeting.

Apatinib-pegylated liposomal doxorubicin combo ups survival in ovarian cancer

Audrey Abella, 20210507100000

The addition of the oral, small-molecule tyrosine kinase inhibitor apatinib to pegylated liposomal doxorubicin (PLD) led to a significant improvement in progression-free survival (PFS) among women with platinum-resistant or refractory recurrent ovarian cancer* compared with PLD alone, according to the results of the APPROVE trial presented at SGO 2021.

ORZORA: Maintenance olaparib shows benefit in BRCA-mutated ovarian cancer

Elaine Soliven, 20210507000000

Maintenance treatment with olaparib showed progression-free survival (PFS) benefit in patients with platinum-sensitive relapsed ovarian cancer (PSR OC), particularly those with somatic BRCA mutation (BRCAm), according to results of the ORZORA* trial presented at SGO 2021.

Lenvatinib + pembrolizumab improves survival in advanced endometrial cancer

Roshini Claire Anthony, 20210506180001

In patients with advanced endometrial cancer with prior platinum chemotherapy exposure, a combination of lenvatinib + pembrolizumab improved survival compared with physician’s choice of treatment (TPC), results of the phase III Study 309/KEYNOTE-775 trial showed.

Maintenance olaparib prolongs survival in ovarian cancer

Audrey Abella, 20210506100000

In women with newly diagnosed, advanced* ovarian cancer and a BRCA mutation**, the progression-free survival (PFS) benefit with maintenance olaparib was sustained beyond end of treatment, according to the 5-year follow-up results of the SOLO1 trial presented at SGO 2021.

Rucaparib trumps chemo for relapsed, advanced BRCA+ ovarian cancer

Rucaparib trumps chemo in relapsed, advanced BRCA+ ovarian cancer

Pearl Toh, 20210430140100

The PARP inhibitor rucaparib significantly improves progression-free survival (PFS) in patients with recurrent, advanced BRCA-positive ovarian cancer compared with standard-of-care chemotherapy, according to the ARIEL4 study presented at the SGO 2021 Meeting.

Fuzuloparib prolongs PFS in patients with recurrent ovarian cancer

Elaine Soliven, 20210430000000

Maintenance treatment with fuzuloparib resulted in significantly improved progression-free survival (PFS) in patients with platinum-sensitive recurrent ovarian cancer, according to a study presented at SGO 2021.

Preterm birth risk elevated after early cervical cancer treatment

Roshini Claire Anthony, 20210421180001

Women with early-stage cervical cancer who conceive ≥3 months following fertility-sparing surgery may be at an increased risk of preterm delivery, according to results of a retrospective study presented at SGO 2021.